Affiliation:
1. I.M. Sechenov First Moscow State Medical University,
Ministry of Health of Russia (Sechenov University); Acad. A. Vein Clinic of Headache and Autonomic Disorders
2. Acad. A. Vein Clinic of Headache and Autonomic Disorders
Abstract
Triptans are a targeted therapy for acute migraine attacks. They are recommended for the treatment of severe attacks when non-specific analgesics are not effective. Four of the seven known triptans with different efficacy and individual tolerability are registered in the Russian Federation. Objective: to determine in an open-label non-comparative single center study efficacy and safety of the new Russian generic tableted rizatriptan 10 mg (Relonova) in real-life clinical practice. Material and methods. Thirty individuals with migraine took part in the study. Patients took rizatriptan to relieve 4 migraine attacks and filled out self-observation diaries and HIT-6 questionnaire before and after therapy. Results. The study involved 30 patients (26 women and 4 men) with mean age of 38.7 ± 9.3 years. Duration of migraine was 19.6 ± 11.4 years, mean number of days with migraine per month was 9.5 [5.25; 16.75]. Most patients (67 %) suffered from episodic migraine and 33 % from chronic migraine; 6 patients (20 %) had migraine attacks with aura; 20 individuals (67 %) received preventive therapy. After taking Relonova medication, pain relief was observed in 86 % of attacks, and in 45 % of cases pain disappeared completely; after 24 hours, pain relief was observed in 87 % of cases, and in 68 % – absence of attacks. A significant decrease in headache intensity was observed within 30 minutes after taking the first dose; in 34 % of attacks the headache returned. Additional analgesic treatment was required in 39 % of cases. Adverse events were observed in 25 % of attacks and were mild. The majority (63 %) of the participants were able to successfully terminate 3 attacks and were responders. Conclusion. Relonova is an effective and safe medication for the relief of migraine attacks.